LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Automation?src=hash" target="_blank"gt;#Automationlt;/agt;--Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced the closing of a $25.6m Series B financing round led by Horizons Ventures with additional investment from Luminous Ventures, SOSV and select other individual and large family office investors. Synthace will use the new funds to drive continued product development and build upon its cell and gene thera.